Podcasts about Monty

Tonight's guest, Monty, has had two cryptid encounters. He's only going to share the first one on tonight's show, because that was his only Sasquatch encounter. The second encounter was with a Dogman. When Monty had his Sasquatch encounter, he was only 16 years old. He had his little brother Robbie and a good friend, John, with him when it happened. What started out as a fun camping trip, up on the mountain behind Monty and Robbie's home turned out to be the most frightening experience either of them had had, until that point. That night, one thing led to another and the next thing the boys knew, they were all  running for their lives down the mountain, trying to make it to the relative safety of their home. What happened? Did they make it? We hope you'll listen to tonight's show and listen to Monty talk about that.If you'd like to check out Monty's YouTube channel, the Unexplained Creature Encounters YouTube Channel, which we hope you will, please visit…https://www.youtube.com/@unexplainedcreatureencountersIf you've had at least one Sasquatch sighting and would like to be a guest on the show, please go to BigfootEyewitness.com and let me know. I'd love to hear from you.If you'd like to help support the show, by buying your own Bigfoot Eyewitness t-shirt or sweatshirt, please visit the Bigfoot Eyewitness Show Store, by going to https://Dogman-Encounters.MyShopify.comI produce 4 other shows that are available on your favorite podcast app. If you haven't checked them out, here are links to all 4 channels on the Spreaker App...My Bigfoot Sighting https://www.spreaker.com/show/my-bigfoot-sighting Dogman Tales https://www.spreaker.com/podcast/dogman-tales--6640134Dogman Encounters https://www.spreaker.com/show/dogman-encounters-radio_2 My Paranormal Experience https://www.spreaker.com/show/my-paranormal-experience Thanks, as always, for listening!

In the week when some cricketers, notably spinners such as Adil Rashid, were bought for astronomical sums in The Hundred auction, Monty Panesar reflects on his first Test appearance exactly 20 years ago. It was in Nagpur in March 2006 where the man who became known as The Sikh of Tweak took his first test wicket - and it was of course none other than the great Sachin Tendulkar. Monty recounts that day, his emotional celebration which became his signature, how Tendulkar presented him with a signed match ball and the impact of that moment. He, Simon Hughes and Simon Mann consider how far the game - which was paying him barely £20,000 at the time - and its rewards have come since. This podcast is available ad-free on The Cricverse Learn more about your ad choices. Visit podcastchoices.com/adchoices

Episode 2774 - Vinnie Tortorich speaks to neurosurgeon Dr. Amir Vokshoor about spinal pain, minimally invasive surgery, how life is motion, and more. https://vinnietortorich.com/2026/03/life-is-motion-dr-amir-vokshoor-episode-2774 PLEASE SUPPORT OUR SPONSORS Pure Vitamin Club Pure Coffee Club NSNG® Foods VILLA CAPPELLI EAT HAPPY KITCHEN YOU CAN WATCH THIS EPISODE ON YOUTUBE - @FitnessConfidential Podcast Vinnie's workout videos are available to purchase! Choose from a 2-day, 4-day, or 6-day workout–or buy all three at a discount! TO PURCHASE VINNIE'S WORKOUT VIDEOS, CLICK THIS LINK: https://vinnietortorich.com/workout Life Is Motion Dr. Amir Vokshoor is a board-certified neurosurgeon who specializes in minimally invasive surgery for adult cranial and spinal disorders. (2:00) Vinnie shares some backstory about his own back and neck pain. He wanted to avoid surgery because what was described to him was not acceptable to him. (10:00) Dr. Vokshoor explains the difficulty in the allopathic system; not all treatments are created equal or worth pursuing. (16:00) Minimally invasive procedures allow the surgeon to enter the body with the least amount of trauma to the healthy tissues as possible. (20:00) They talk about stretching and strengthening the iliac and psoas muscles. (31:30) They discuss taking collagen peptides. (38:00) They discuss a horse named Monty and his ligament injury. (40:00) Bioavailability of supplements and gut health are very important for tissues. (42:00) What do we know about NAD? (44:00) Dr. Amir emphasizes that "life is motion"! Good, whole foods, activity, and wellness are so important. Balance and grip strength are good indicators of overall strength. There are various reasons why grip strength is important. (54:00) Vinnie asks about certain chiropractic moves that are popular on social media. (56:00) Dr. Amir can be found at https://drvokshoor.com and can be hired for a consultation to review a spinal MRI with you. He can also be found on Instagram at @drvokshoor To accommodate new listeners, the NSNG® VIP group is open again for a *very* limited time! https://www.nsngvip.com/join. It will open from Monday, March 9, through Sunday, March 15th, 2026, at midnight. Join while it is open! The membership includes 2 group calls with Vinnie, free resources like Vinnie's video workouts and workout trackers, and a supportive community for encouragement and accountability. A New Sponsor Jaspr Air Scrubbers has a discount code, VINNIE, that gets you $300 off for a limited time. Jaspr offers a lifetime warranty. Go to Jaspr.co for more information or to purchase. (1:05:00) You can book a consultation with Vinnie to get guidance on your goals. https://vinnietortorich.com/phone-consultation-2/ More News Serena has added some of her clothing suggestions and beauty product suggestions to Vinnie's Amazon Recommended Products link. Self Care, Beauty, and Grooming Products that Actually Work! https://www.amazon.com/shop/vinnietortorich/list/3GPVU29UHHPMY?ref_=aipsflist Don't forget to check out Serena Scott Thomas on Days of Our Lives on the Peacock channel. "Dirty Keto" is available on Amazon! You can purchase or rent it here.https://amzn.to/4d9agj1 Please make sure to watch, rate, and review it! Eat Happy Italian, Anna's next cookbook, is available! You can go to https://eathappyitalian.com You can order it from Vinnie's Book Club. https://amzn.to/3ucIXm Anna's recipes are in her cookbooks, on her website, and on Substack —they will spice up your day! https://annavocino.substack.com/ PURCHASE DIRTY KETO (2024) The documentary launched in August 2024! Order it TODAY! This is Vinnie's fourth documentary in just over five years. Visit my new Documentaries HQ to find my films everywhere: https://vinnietortorich.com/documentaries Then, please share my fact-based, health-focused documentary series with your friends and family. Additionally, the more views it receives, the better it ranks, so please watch it again with a new friend! REVIEWS: Please submit your REVIEW after you watch my films. Your positive REVIEW does matter! PURCHASE BEYOND IMPOSSIBLE (2022) Visit my new Documentaries HQ to find my films everywhere: https://vinnietortorich.com/documentaries FAT: A DOCUMENTARY 2 (2021) Visit my new Documentaries HQ to find my films everywhere: https://vinnietortorich.com/documentaries FAT: A DOCUMENTARY (2019) Visit my new Documentaries HQ to find my films everywhere: https://vinnietortorich.com/documentaries

Bum N Zilly finally got around to releasing this episode that we recorded last Friday March 6th. Hope ya'll enjoy the silly outdated sports takes and reviews! 00:11 "Arnold on the Run" and show intro (Suh) 01:41 Terrion Arnold in some trouble?  03:20 Bootless Byll breaks some NFL news  06:33 Bum's LiveScope purchase  08:23 "Price is Right" 12:37 Jim Carrey  13:47 Taylor Decker released and Monty traded  17:11 Free agency potential pick ups for the Lions  22:28 Vikings talk (Brady vs Paul) 24:43 MN State Hockey  26:50 Sabres roaring out of the NHL break  33:16 Sleepy Joe's tweet 34:33 Timberwolves talk  36:04 Laker's losing streak and Ayton ain't him  40:19 NBA championship odds  41:20 WWE Elimination Chamber review  47:16 Quick Winnie story 48:24 Back to the Elimination Chamber review  52:11 Danhausen's list of demands and a curse (Best selling T-shirts WWE) 56:00 The men's elimination chamber review (Random WWE chatter) 59:01 Seth Rollins, Daniel Bryan, Spike Dudley and Lesnar chatter  1:02:58 Randy wins the Men's chamber match  1:04:42 Demolition WWE HOF bound! 1:06:38 Thumb tack spots in wrestling and old PPVs (Mick Foley)  1:10:50 Initial thoughts on Dire Straits "Love and Gold" ("I Need You" Lynyrd Skynyrd) 1:13:13 Outro  1:14:27 Demolition tribute          Want to get your thoughts involved with the podcast?Check us out on Twitter/X @BumNZillyshowEmail at bumandzillyshow@gmail.com

Monty and Nick preview the weekend as all sixteen teams play conference foes. They provide their picks and X-Factors for the match-ups as well.

The 2026 season for the Lions and 5th season for this here podcast begins now. The Lions lose a lot of big names, but gain a few back in the process, we recap all the moves and give our thoughts on what this all means for the future. Lets go Lions.

This week, we talk thirst traps and fashion - including the jeans we refuse to wear. Mel has hit peak povo home reno, and Monty gives us an update on her TMS treatment. Enjoy! Fancy supporting us on Patreon? Find out more here. Follow us and get in touch on Instagram here. Follow us on Facebook here.See omnystudio.com/listener for privacy information.

Todays Guest Monty Nero brings us his Cyberpunk tale Chrome Roses from across the pond in Scotland. A world aptly named the Tract where society was broken in half by a pandemic, no law enforcement, decisions are made by social media polls and ratings, physical touch has abandoned for Husks-an advance way of feeling because of fear from the outside world. A rogue detective named Kramm freelances his way at solving a murder although solving a crime in this world is transactional and monetary. Gig economies and Digital Identity are the way. Monty provides the artwork of this vast world as well detailing characters where some have replaced their flesh to become something of a total mechanism, body and soul.Written, Artwork, and Lettered by Monty NeroSupport this podcast at — https://redcircle.com/the-faqs-project-hosted-by-james-grandmaster-faqs-boyce/donations

Monty, Micah, and Nick recap the opening weekend of ACC play as the baseball season rolled on.

Celebrated for his victories in North Africa and Europe, Bernard Montgomery built a reputation for meticulous planning and caution that many soldiers admired. But his record was not without controversy, from tense rivalries with his allies to the failed gamble of Operation Market Garden. Was 'Monty' truly one of the war's great commanders, or has his reputation been shaped by myth and wartime propaganda?This is the second episode of our "Commanders" series, where we dig into the lives and decisions of five legendary WWII commanders. To guide us through the story of Monty, we're joined by Peter Caddick-Adams, a military historian and author specialising in the Second World War.Produced by James Hickmann and edited by Dougal Patmore.Dan Snow's History Hit is now available on YouTube! Check it out at: https://www.youtube.com/@DSHHPodcastSign up to History Hit for hundreds of hours of original documentaries, with a new release every week and ad-free podcasts. Sign up at https://www.historyhit.com/subscribe.You can also email the podcast directly at ds.hh@historyhit.com. Hosted on Acast. See acast.com/privacy for more information.

It's Story Time, our weekly walk through cricket history. This week, the man who was Test captain but never knew – an emblem of his peculiar life, told wonderfully by Daniel Norcross. Adam finds an excuse to go back to a beautiful line on contemporary of Bradman who had the knack of stepping up when it mattered most. Later, some love for the long lost tour game, those played in Australia and some others played by Shane Warne. Your Nerd Pledge numbers for this week: 189.00 - RichieB 13.19 - Lachlan Pryor 2.32 - Andrew Maxwell 4.09 - Gordon Anderson Support the show with a Nerd Pledge at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠patreon.com/thefinalword⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and win a case of Stomping Ground or a pack of Step One jocks Browse the beers at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠stompingground.beer⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Or learn more about buying shares in Stomping Ground is right for you https://onmarket.com.au/offers/stomping-ground-eoi Stop snoring with 10% off a Zeus device: use code TFW2026 at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠zeussleeps.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Get 10% off BIG Boots UK boots and socks at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠bigboots.co.uk/?ref=thefinalword⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Maurice Blackburn Lawyers - fighting for workers since 1919: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠mauriceblackburn.com.au⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ CBUS Super - Build your something. Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://cbussuper.com.au⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ to sort your superannuation. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Get your big NordVPN discount: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠nordvpn.com/tfw⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Get 10% off Glenn Maxwell's sunnies: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠t20vision.com/FINALWORD⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Find previous episodes at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠finalwordcricket.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Title track by ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Urthboy⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Learn more about your ad choices. Visit podcastchoices.com/adchoices

Hosts Pastor Robert Baltodano and Pastor David Guzik Question Timestamps: Harry, MS (3:25) - Are we supposed to speak in tongues? Jasper, email (9:17) - Why is it okay to use "I am" when referring to God? Why is it not okay to pronounce the name "YHWH?" Richard, email (12:30) - Why did Jesus tell his disciples to buy a sword, if he didn't intend for them to use them? Sarah, email (15:39) - Can the enemy use our children to spiritually attack us? Stacy, email (19:53) - What proof do we have that the Bible is God's word? George, email (23:59) - When Peter refers to a "new heaven," what does that mean? Monty, email (25:16) - How do I know when God is approving a relationship? How do I find a good woman? Anonymous, caller (33:57) - How do you build up a desire to pray, when the things you have prayed for didn't happen? How do you know when God is saying "no" versus spiritual warfare? Jeremy, NJ (43:58) - Why does Proverbs refer to wisdom in female terms, if Jesus is wisdom? Frank, email (47:29) - Are we allowed to use Scripture in a court case? John, NJ (49:04) - How old was Joseph when he passed away? Where was Jesus for the eighteen year gap between childhood and His ministry? What happened to the third night if Jesus was crucified on Friday? Eric, NJ (53:54) - Was the Tower of Babel really built all the way to the sky? Ask Your Questions: Call: 888-712-7434 Email: Answers@bbtlive.org

Sermon Notes Date: 03/08/2026 Preacher: Monty Simao, pastor Study: Matthew Key Text: Matthew 2:13-23 Description: It is one of the darkest scenes in the early life of Christ. A new King has been born in Bethlehem. But the throne in Jerusalem is already occupied. Today on Scandia Bible Church Podcast, Pastor Monty Simao continues our […]

The best time of the year is here! Conference tourneyʻs get into full swing as we get ready for the brackets to be released on Sunday! Plus, NBA Hoops, NFL Free Agency and Monty shares his love for the World Baseball Classic! Letʻs get after it!

Send a textIn this third season, I am sharing chapters from my short novel “Zunzuncito's Adventure”. This week is chapter 6! Zunzuncito is on a mission to find the magic flower that will grant his wish to be big. He spoke with the wise snake Majá and now he knows where he must go, but how will he get there? Thankfully, he has a small sidekick, the tiny frog Monty, to help him out.This story is told in the the present tense. Repeated words and phrases include lake, fish, fly, swim, and right. No matter where you are in your language journey, stories will help you on your way. You can find a transcript of the story and read along at https://smalltownspanishteacher.com/2026/03/09/simple-stories-in-english-zunzuncitos-adventure-chapter-7/ Thank you for listening, and a HUGE thank you for your support. I really enjoy creating and sharing simple, comprehensible stories. If you would like to help me in that endeavor, consider donating to @Small Town Spanish Teacher on Venmo, PayPal, or Buy Me A Coffee https://www.buymeacoffee.com/SpanishTeacher .

To support this ministry and help us continue to reach people all around our region, click here: http://bethel.ag/give/Stay Connected Website: www.bethel.ag Bethel Church Facebook: www.facebook.com/bethelchurch605/ Bethel Church Instagram: www.instagram.com/bethelchurch605/

We were delighted to be joined by Ewan Paton off the back of his first day as Media & Communications Manager for the Club. Huge thanks to Baz who also filled in on Monty's absence - a true legend of the fans. Thanks to our sponsors ⁠Allied Surveyors Kilmarnock⁠: https://www.alliedsurveyorsscotland.com/office/kilmarnock/For home reports or property advice, contact Nick Davis on 01563 572341, email ⁠nick.davis@alliedsurveyorsscotland.com⁠, or visit their John Finnie Street office.

The guys start this week's Best of Valenti with their reactions to the Lions trading away David Montgomery. Plus, they reacted to the new TV/streaming service for the Red Wings and Tigers, Mike offered the people 2 Pistons options, and much more!

Episode 593! It's WWE Elimination Chamber! James, Monty and Gina are here for all things WWE! We review the Chamber and catch up with Raw and Smackdown! Plus lot's more! Enjoy!!

We have a short but sweet episode of Where's That Bar Cart this week, where we cover an unusual hole-in-one at TGL, Monty and Nick hit a simulator together, parking lot fights, Darryl Sittler, and some goals for the upcoming golf season. Thanks to Comedy Records and to each and every one of you who listens, watches, and supports our podcast. Please subscribe to our YouTube channel @ComedyRecords. Swing well out there. Follow us at:- @wheresthatbarcart- linkt.ree/wheresthatbarcart- @dpurcomic- @montymofoscott- @nickdurie- @comedyrecordsMusic by Devin BatesonThank you to Comedy Records

Monty, Micah, and Nick preview the first slate of ACC play and provide X-Factors as the season starts to heat up.

Dr. Monty Pal and Dr. Andrea Apolo discuss practice-changing studies and other novel approaches in bladder, kidney, and prostate cancers that were presented at the 2026 ASCO Genitourinary Cancers Symposium. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist, professor and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles.  And today is super exciting, we're highlighting key abstracts that were presented at the 2026 ASCO GU Cancers Symposium, and I'm just delighted to be joined by the chair of this year's meeting, who is also a dear friend, Dr. Andrea Apolo. Dr. Apolo serves within the Center for Cancer Research at the NCI as head of the Bladder Cancer Section, and she is also acting deputy chief of the Genitourinary Malignancies Branch.  Welcome, Andrea, it is so great to have you on the podcast. Dr. Andrea Apolo: Oh, thank you so much for having me. What a great ASCO that we had, it is really exciting, lots of really great data. So I look forward to chatting about it. Dr. Monty Pal: Excellent. And you know, our full disclosures are available in the transcript of this episode in case our listeners want to have a peek.  The theme of this year's GU meeting was "Patient-Centered Care: From Discovery to Delivery." I love that theme. And really, this is one of the most competitive meetings out there, more than 850 abstracts being presented on high-impact science. Andrea, I just wanted to get right into it and dive into what I think we both felt were some of the most exciting abstracts of the meeting.  And the first of those is one that I know is near and dear to your heart, being a bladder cancer expert yourself, and that is the KEYNOTE-B15 study presented by Matt Galsky. Can you give us a flavor for what that study entailed and some of the key results? Dr. Andrea Apolo: Yeah, I think this was kind of the missing study that we have been waiting for since we saw the EV-302 data in metastatic disease in the frontline setting. We wanted to know how well this combination would work in muscle-invasive bladder cancer patients. And we saw half of that puzzle, you can say half of the piece of the puzzle, when we saw the data at ESMO, the EV-303 data in patients that were cisplatin-ineligible. And then now we are getting the full story with patients that are platinum-eligible, cisplatin-eligible, with the EV-304 data. So that study randomized patients to receive chemotherapy, so different than the EV-303 where the patients were randomized just to receive the radical cystectomy. These patients were randomized to receive neoadjuvant EV plus pembro and then adjuvant EV plus pembro versus neoadjuvant gemcitabine and cisplatin with no adjuvant component to the control arm. So I think this is a really, really important study. Dr. Monty Pal: And share with us some of the results because this in my mind is definitely practice-changing. This is one of those studies that I think you walked into the office on Monday and you are like, "Okay, this is what I am doing now," right? Dr. Andrea Apolo: Yeah. So the study was positive. The primary endpoint was event-free survival, and it met the primary endpoint. The secondary endpoint of overall survival was also met. So really, really great results. Consistent with what we saw with EV-303, the median event-free survival was not reached for the EV plus pembro arm, and it was 48 months for the patients receiving gem-cis. And then looking at the 24-month estimated event-free survival, it was 79% for the EV plus pembro and 66% for the chemo, the gem-cis arm. And that was a hazard ratio of 0.5. So that is really exciting. That is the event-free survival. And then the overall survival, the medians were not reached for either arm, but when you look at the 24-month estimated overall survival, it was 87% for the EV plus pembro versus 81% for the gem-cis, and that was a hazard ratio of 0.65. So very positive study.  And then another question that we had was the pathologic CR rate. Very consistent with what we saw with the EV-303, the pathologic response rate was about 56% for the patients that received EV plus pembro and about 32%, 33% for the patients that received gem-cis. So very consistent with the findings that we have been kind of seeing in phase 2 studies, and this is a pT0N0, so that is important. Dr. Monty Pal: So Andrea, you know, I think that the big question in folks' minds is at this point, we see the data from NIAGARA, cis-gem-durva, we have now seen this data. Put it into context for us. Is there a patient in this day and age who maybe shouldn't get IO altogether, who should maybe get the NIAGARA regimen as opposed to EV-pembro in this context? What are your thoughts there? Dr. Andrea Apolo: Now, that is a great question. I would say with this data, it is very enticing to give EV pembro to our patients in the perioperative setting, and for that to be the new standard of care for all patients, regardless of cisplatin eligibility. So similar to what we saw with EV-302 really changing the standard of care in the frontline setting, I think these two studies, the EV-303 and the EV-304, change the standard of care for patients with muscle-invasive bladder cancer in the perioperative setting, and this should be the new standard of care if the patients don't have a restriction to receiving an immunotherapy. Dr. Monty Pal: I totally agree with that assessment. It is great to hear it from the expert's mouth as well. Thanks a lot for that, Andrea.  The next abstract I wanted to tackle is one that is, I would say, near and dear to my heart because I know these folks really well. It is led by the SWOG group, and this is SWOG S1602. The number there for the audience gives you a sense of how long the study has been running for. The 16 prefix means it is something that we kicked off back in 2016. So this study is really 10 years in the making, right? So Rob Svatek presented this data. It is interesting, right, because it addresses this issue of the BCG (Bacille Calmette-Guérin) shortage, right, where we have needed to sort of rely potentially on other alternative sources or regimens and so forth. Tell us about this trial, Andrea. Dr. Andrea Apolo: This is one of my favorite studies. We talked about putting it in the main oral abstracts, but we put it in one of the educational sessions that talked about non-muscle-invasive bladder cancer because we thought that would be the best audience for it. But it doesn't take away from how important this abstract is, and the tremendous effort that went into the study. Almost a thousand patients enrolled. I think 984 were eligible to enroll in this study. So it is a very high enrolling, randomized, cooperative group study in high-grade non-muscle-invasive bladder cancer. And really the study was designed to address two questions. One is the BCG shortage and can we use a different strain, Tokyo versus TICE? And whether there is a priming effect if you gave intradermal BCG to patients with non-muscle-invasive bladder cancer, can that enhance the effect if you gave it a little bit earlier? I think the study is really important, and it met its primary endpoint, which was it is not inferior to TICE. The findings were really terrific in terms of the outcomes. Numerically. When you look at the endpoint, it looked like the Tokyo strain was as good, if not maybe a little bit better, but not statistically significant than the TICE. And then they broke it down by carcinoma in situ, they broke it down by papillary tumors, and the Tokyo strain was non-inferior in both of those instances. But interestingly, the intradermal BCG did not change outcomes. There was really no priming effect, which was really backed up by pre-clinical data that there would be, but there wasn't a priming effect when the intradermal BCG was given in the Tokyo strain. So that was a really, really interesting finding. But a great study, really important outcomes in the field for non-muscle-invasive bladder cancer. Dr. Monty Pal: Totally. And it just seems like we can't get away from BCG, right? You know, as hard as we try, I mean, I appreciate the studies that sort of build on it that are emerging right now, but it seems like BCG at least for the foreseeable future is kind of here to stay, right? Dr. Andrea Apolo: It works. It is one of the most effective treatments we have for non-muscle-invasive bladder cancer. So, you know, I think it is here to stay and, you know, we need to find alternatives in terms of strains so we don't deal with this shortage that we have been dealing with for so many years now. Dr. Monty Pal: Yeah, indeed. Moving on to some of the other highlighted studies from the meeting, you had mentioned the EV-303 data, so we probably don't need to rehash that study design in much detail. But there was also a rapid oral abstract presented by Dr. Ullén that I think is of interest here, right, that really hones in on pathologic outcomes and DFS from that trial. Do you mind just outlining that for our listenership? Dr. Andrea Apolo: This is the KEYNOTE-905, also known as the EV-303 study. This is a follow-up to the EV-303 data looking at the pathologic response rates, looking at the downstaging effect, looking at the surgical margins after treatment with the neoadjuvant EV plus pembro in the 303. Now, remember in the 303, patients got three cycles of neoadjuvant EV plus pembro and then six cycles in the adjuvant setting. A little bit different than the 304, where they got four cycles, which is really kind of the standard in the neoadjuvant setting, and then five cycles in the adjuvant setting. So still a total of nine cycles. But in the 303, the treatment arm had no systemic therapy, so it was just radical cystectomy. And they looked at the negative margins that you get with the EV plus pembro treatment, which was 92.6% versus 79% with patients receiving just the surgery alone. And then the pathologic CR rate, there was more follow-up on that, it was 57% for the patients receiving EV plus pembro, and as we would expect, about 9% for the patients that just went on to surgery alone because you can achieve a pathologic response rate with TURBT alone. Then they looked at the pathologic downstaging, so anything less than a pT2, and that was 66% in the patients that received the EV plus pembro. So very interesting findings, and it is also really just nice to have now the EV-304 data, like I was saying, there were two pieces of it, the cisplatin-eligible and the cisplatin-ineligible, and just to have those contemporary controls are really important. How did the cisplatin-ineligible do versus the cisplatin-eligible patient in terms of the event-free survival and in terms of the overall survival? So I feel like now we have all of this data that we can kind of put together in the perioperative setting and we can really inform our patients a little bit more about their outcomes depending on whether they are cisplatin-eligible or not, which you know cisplatin-ineligible patients often just, they are sicker, they may have obstruction, their tumors may be larger, they just tend to be a more delicate population than the cisplatin-eligible patients. So not surprisingly, you know, we see that in the EV-303 the disease-free survival for the patients is pretty poor. So the disease-free survival that was reported for this follow-up of the specific abstract was 23.6 months for the patients that just got surgery, and it was not reached for the patients that had the EV plus pembro, and that was a hazard ratio of 0.37. Dr. Monty Pal: Excellent, excellent distillation. So Andrea, in the interest of time, I mean, we could probably talk about bladder cancer forever, but I am going to move us on to the subject of kidney cancer. We have two late-breaking abstracts, LITESPARK-011, which looked at lenvatinib and belzutifan versus cabozantinib in the advanced setting, and then we have an adjuvant study, LITESPARK-022, that looked at pembrolizumab with or without belzutifan in the adjuvant setting. Both studies positive. One for progression-free survival, the other for disease-free survival. Both I think making a big dent in how we treat kidney cancer. Can you tell us a little bit about that? Dr. Andrea Apolo: Yeah, we have been waiting for these trials for a long time. So one of the things that we have been talking about at GU ASCO is to have plenary sessions. And if we would have had a plenary session, these two abstracts would have been part of it because they are important data, really big studies where we are trying to improve the outcomes of our patients with kidney cancer. So the first one, the LITESPARK-011, like you said, this is for advanced renal cell carcinoma, clear cell renal cell carcinoma, where we really don't have a standard of care after IO therapy, right? So we give IO-IO, we give VEGF-IO, but we don't really have a good standard of care. We usually give monotherapy TKIs. So the combination of belzutifan and lenvatinib versus what a standard of care is, cabozantinib, is really an important question to ask. And you know, this is a pretty large study, about 750 patients were randomized. And belzutifan plus lenvatinib demonstrated an improvement in progression-free survival and overall survival versus cabozantinib, but not overall survival, at least not yet, is what the authors are saying. So for the progression-free survival, the hazard ratio was 0.7 and it was 14.8 months for the combination, belzutifan plus lenvatinib arm versus cabozantinib, which was 10.7 months. So I think that is significant. And for the overall survival, it did favor the combination again with a hazard ratio of 0.85. The median was 35 months versus 28 months for the monotherapy cabozantinib, but it did not reach statistical significance. And the authors said that this will be further tested at a final analysis, these were the interim results.  And for the overall survival, the overall survival was 53% for the combination versus 40%. This is significant. And the CR rates were lowish for both of them, it was like 5% for the combo and 1% for cabo monotherapy. So I think that the findings are important because we don't have a standard of care. And although there is no survival benefit, there was a trend. So I think this could be considered in patients that are fit, a treatment option for these patients in the later line settings. Dr. Monty Pal: Great points. I mean lots of great discussion around toxicity as well as efficacy. I mean certainly this is a regimen that may not be suitable for every patient in my portfolio, but certainly one to consider.  Now Andrea, let's shift focus to LITESPARK-022, the adjuvant trial that I mentioned previously. So this is again looking at pembrolizumab with or without belzutifan, met the primary endpoint of disease-free survival. What are your impressions there of the data? Dr. Andrea Apolo: Yeah, the data looks great. And this was a really large study, 1,800 patients were randomized, and the study met the primary endpoint of disease-free survival, benefiting the combination of pembro plus belzutifan. And that is really terrific. The medians were not reached for either arm. And in terms of the overall survival results, also the medians were not reached, but the hazard ratio was 0.78 and did not reach a statistical significance. So there was again a statistically significant improvement in disease-free survival for the combination of pembrolizumab plus belzutifan, but not an overall survival benefit.  So I guess, Monty, you know, we can kind of talk about what that means. There was a lot of discussion about belzutifan and some of the side effects, specifically anemia and managing anemia in this setting and requirements for transfusions. Generally, the authors said it was well tolerated, but we know that combination studies do have more toxicity. So it may be a select group of patients again, similar to the advanced setting, where we opt for a combination, possibly until we see more follow-up data in terms of the overall survival. Dr. Monty Pal: I have to agree with you. You know, in my group, we have been talking about a lot of pembrolizumab-based studies that are running right now, some through the NCI, some, you know, our own sort of homegrown investigator-sponsored trials, and you know, I think for the foreseeable future we are comfortable just maintaining pembrolizumab. Things might change if, for instance, we ultimately see a survival advantage emerge, but I just have my own personal doubts around that, that will be interesting.  Okay, so now we are going to move to the last disease category that we are going to cover, which is prostate cancer. So there, we have the long-awaited results from the PEACE-3 study. These are the final OS results from this trial looking at enzalutamide with or without radium-223 in metastatic castration-resistant prostate cancer. So Andrea, would love to get your perspectives on this. Dr. Andrea Apolo: Yeah, so this study had been presented before and we had seen positive results for the combination of enzalutamide and radium with some interim overall survival results also showing a benefit. But like you said, these are the final results with a median follow-up of 58 months. So it was really nice to see the final results. And with the combination of enzalutamide and six cycles of radium, it did show an improvement in overall survival with a hazard ratio of 0.76. The median overall survival increased from 32.6 months to 38.2 months with the combination. So that is really great. There was some crossing over of the overall survival curves around 18 months was still seen. And again, there was also an improvement in the rPFS with a hazard ratio of 0.71, and the median rPFS improved from 16.4 to 19 months with the combination. So, you know, we have been awaiting the final results, but we kind of knew a lot about the benefits of the combination. And it is something that is kind of slowly trickling into the community in terms of adapting it and using it. There is more buzz now about it and I think these overall survival results will hopefully shift the community into incorporating the combination in these patients. Dr. Monty Pal: Brilliant. So well said. I mean, Andrea, congratulations on a terrific meeting. You have really done it again. Incredible, incredible output from this year's ASCO GU. I just want to thank you for joining us on the program today. Dr. Andrea Apolo: Oh, thank you so much for having me, Monty. It was really a joy to work with the ASCO team and with all the investigators and the Education Committee and the Scientific Committee. Everyone was really outstanding. So to me it was an honor to be part of this meeting, and I am so happy that it was so successful and really presented some amazing data that I think will be practice-changing to our patients. Dr. Monty Pal: Oh, thanks a ton. And also a huge thanks to our listeners. If you enjoyed the content of today's podcast, please don't forget to like and subscribe to our channel wherever you listen to podcasts. Thanks so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:     Dr. Monty Pal   @montypal  Dr. Andrea Apolo @apolo_andrea  Follow ASCO on social media:          ASCO on X    ASCO on Bluesky         ASCO on Facebook          ASCO on LinkedIn          Disclosures:       Dr. Monty Pal:      Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview     Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical     Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis     Dr. Andrea Apolo: No disclosures to report.

Happy Valentine's Day! Jeff emphasizes the importance of practicing your faith in your marriage. This conversation presents some ideas for three date nights... with Monty and Jeannine Mora of The Favorite Marriage. Perhaps the most critical element to rebuilding our culture, learn how the Church and help rebuild marriages. https://thefavoritemarriage.com/our-storySee omnystudio.com/listener for privacy information.

Hour 3 of the Chris Hand show | Thursday 03-05-26See omnystudio.com/listener for privacy information.

SummaryIn this episode, Jason Harwood and Jacob Litton analyze recent NFL trades, focusing on the Detroit Lions' strategy, player moves, and the implications for team building. They compare trade values, discuss free agency plans, and explore the Rams' approach to roster management. In this episode, Jason and Jacob analyze the latest NFL free agency moves, trade rumors, and team strategies. They discuss potential signings, player performances, and the impact on Detroit Lions' roster planning, providing insights into the NFL offseason dynamics.Visit us on X: @talkinggritpodJason - @Jason_TGPodJacob - @jmallittonYouTube - www.youtube.com/@TalkingGritFacebook - https://www.facebook.com/profile.php?id=61559912376520Reddit - https://www.reddit.com/r/Talkinggritpodcast/#detroitlions #NFL #football #NFCNorthChapters00:00 Introduction and Overview01:32 Initial Reactions to David Montgomery Trade04:20 Analyzing the Trade Compensation06:38 Comparative Analysis of Running Back Trades10:17 David Montgomery's Future and Team Dynamics13:51 Organizational Philosophy and Player Care17:00 Kicker Dynamics and Future Considerations27:54 Kicking Game Improvements28:41 Contract Restructuring and Free Agency Expectations30:59 Combine Rumors and Team Strategy32:34 Comparing Team Building Strategies: Lions vs. Rams35:16 Evaluating Trade Opportunities and Player Impact39:59 Free Agency Market Dynamics and Player Cuts49:37 Analyzing Free Agent Rankings and Team Needs53:48 Defensive Strategies and Linebacker Needs56:35 Exploring Edge Rushers and Defensive Linemen58:01 Offensive Line Considerations59:50 Running Back Options and Free Agency01:02:11 Safety Needs and Potential Signings01:04:32 Free Agents from Arizona and Team Dynamics01:07:30 Final Thoughts on Team Prospects and Future Moves

Get tickets to Deep Tempo Records 1st Birthday (27/03 Manchester) - https://ra.co/events/2336496Support us on Patreon https://www.patreon.com/DeepTempoGet Deep Tempo Merch - https://deeptempo.co.uk/merchEvents and Tickets - https://deeptempo.co.uk/eventsTo book us for your next event, please contact helen@enki-agency.co.uk :)• TRACKLIST •ENiGMA Dubz x Mystic State - Backchat Monty - Bug - (Bandcamp)N-TYPE - HOTPLATE - DUBJOKER - MAELSTROM - ???Cimm - No Friends in 818 - Close CallsFlava D - Dem Not Ready - UKFWraz & Truth - Arrakis - Deep Dark DangerousSpektiv - Do It Right - BuntaiOtto Hood - Bodies Keep Secrets - Ray Collect Records Tranzmita - Headbang - Drippyboiii RecordingsRunaaki - Sly Grin 2025 VIP - Sir Dub MuzikTailor Jae - Dial Tone - Manuka Bidl - Reverse - Illicit Envy - Medieval - Dial 1 MusicKlippee x Repulsion - SwingyThingy - Silent Motion RecordsD8 - 210 (PS) - Concrete LawChrizpy Chriz - Arcade Of Sadness - Incurzion AudioSootie - Guts - Deep Tempo RecordsCessman + Deapoh - Red Clouds - Dubliminal Teffa - Milky Way - ZOOO RECORDSSEMPA - ACES - Pull Up RecordingsNatty D & Goosensei - Original Sound MYTHM - WHISPERS FT. ORACLE GREY - Deep Medi Musik• OUTRO •Pent1 - Breath Control - Size10 Records• FOLLOW US •Instagram - https://www.instagram.com/deeptempo140/Soundcloud - https://soundcloud.com/deeptempo140#deeptempo #dubstep #podcast

ROUGH PATCHES. On this episode of the Came to Believe Recovery Podcast Tom and Monty discuss the truth about going through those times in our lives when it feels like a struggle, a challenge or a fail. We all have either gone through times like these, are currently going through them or will in the future. We also answer some emails from our listeners. Closing song: Awesome God by the VanZant Band. #recovery #alcoholic #twelvesteps #wedorecover #addiction 

Fantasy Football show for Mar 3, 2026. Free Agency preview and predictions! Plus, David Montgomery traded, Jahmyr Gibbs outlook, and other big NFL News! Andy, Mike, and Jason discuss which free agents and landing spots could have a major impact on 2026 fantasy football drafts! Manage your redraft, keeper, and dynasty fantasy football teams with the #1 fantasy football podcast. (00:00) Intro (05:20) Combine Takeaway (15:10) NFL News (41:00) Free Agent Predictions (43:45) Quarterback Predictions (47:50) Running Back Predictions (53:55) Wide Receiver Predictions (56:20) Tight End Predictions Connect with the show: Subscribe on YouTube Visit us on the Web Support the Show Follow on X Follow on Instagram Join our Discord Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

March 2nd, 2026 Follow us on Facebook, Instagram and X Listen to past episodes on The Ticket’s Website And follow The Ticket Top 10 on Apple, Spotify or Amazon MusicSee omnystudio.com/listener for privacy information.

NEWS: Makai Lemon concern? Monty, Vikings QBs, Tua, Achane

HEADLINES: Texans get Monty/Chiefs cut Taylor/Uconn Women perfect again

On today's episode, everyone is fully medicated. We get 2 -- 3? -- cold opens because Ellyn is thirsty. Ellyn calls 2 gays and a Thermos. Daisy calls Kurt... and Monty. Abort mission! Act normal, not horny! Oh right, we're supposed to be talking about Love is Blind. Blahzayblah... Some couples get engaged. Ladies wear questionable shoes. But most importantly: THESE MEN ARE THE WOOOOORSSSSSST! We are all gravely concerned for the women of Ohio if this is the best Netflix could find. How was Chris even able to reach high enough to get that much audacity off the shelf? And who the fuck does Alex think he is? Daisy is going to write a strongly worded letter to Mr. Netflix, and Ellyn is going to submit an expense report to GBC for her anxiety meds.

Monty and Nick review their weekend X-Factors, talk ACC vs SEC results, and play Buy, Sell, or Hold on several blanket statements about teams.

6:00 HOUR: How do the Lions replace Monty? Costa's Honolulu Blueprint

3/3/26 - How do the Lions fill Monty's shoes? Costa's Honolulu Blueprint, Two Grand Slam, Are you on board with Detroit SportsNet?

Texts on Lions and Wings.

Red Wings trade, Eat That, WBC talk

Sermon Notes Date: 03/01/2026 Preacher: Monty Simao, pastor Study: Matthew Key Text: Matthew 2:1-12 Description: Have you ever noticed how pressure reveals what's really inside a person? Put someone in a crisis… Put someone in a moment of decision… Put someone face-to-face with authority… And the heart is exposed. Today on Scandia Bible Church Podcast, […]

Lions future.

Did the Lions get enough for Monty?

Monty was beloved in Detroit.

Who's the next Monty?

Did the Lions get enough?

Do the Lions need to replace Monty?

Post combine thoughts, Wings trade rumors.

Join us again for a trip to Alaska's wilderness. Our friends Monty Browning and Bryan Burkhardt were once again kind enough to record and share their 2025 Alaskan Moose hunt. With the 2025 deer season over, we are excited to bring their hunts to you. Their incredible day-to-day adventures are the things most of us only dream about. So set back and join them by the fire as they share another Alaskan Moose Adventure.

Join Debbie Loucks on a special episode of Horsemanship Radio.Each month, we'll delve into a chapter from Monty Roberts' insightful book, Horse Sense for People. Discover how Monty's revolutionary, non-violent communication techniques with horses offer invaluable lessons for human relationships, business, and personal growth. This series aims to share Monty's timeless wisdom and inspiring stories with everyone, free of charge. Tune in on the 1st and 15th of every month for new episodes of Horsemanship Radio!Horsemanship Radio 298:Show Host: Debbie LoucksTitle Sponsor: HandsOn Gloves, All-In-One Shedding/Bathing/Grooming GlovesPhotos used with permissionPurchase your own copy of Horse Sense for PeopleLearn more about Good Horsemanship at Monty Roberts EQUUS Online University Monty's CalendarPlease follow Monty Roberts on FacebookFollow Monty Roberts on Twitter or on InstagramSee more at: MontyRoberts.comHear all the shows on the Horse Radio NetworkSupport the show

Join Debbie Loucks on a special episode of Horsemanship Radio.Each month, we'll delve into a chapter from Monty Roberts' insightful book, Horse Sense for People. Discover how Monty's revolutionary, non-violent communication techniques with horses offer invaluable lessons for human relationships, business, and personal growth. This series aims to share Monty's timeless wisdom and inspiring stories with everyone, free of charge. Tune in on the 1st and 15th of every month for new episodes of Horsemanship Radio!Horsemanship Radio 298:Show Host: Debbie LoucksTitle Sponsor: HandsOn Gloves, All-In-One Shedding/Bathing/Grooming GlovesPhotos used with permissionPurchase your own copy of Horse Sense for PeopleLearn more about Good Horsemanship at Monty Roberts EQUUS Online University Monty's CalendarPlease follow Monty Roberts on FacebookFollow Monty Roberts on Twitter or on InstagramSee more at: MontyRoberts.comHear all the shows on the Horse Radio NetworkSupport the show

Soly, Neil and Tron have searched far and wide for rules controversies from recent, and not so recent, golf history.  Enjoy this look at some of our favorites including Tiger's drop on 15 at Augusta in 2013 as well as some dust ups involving the Walrus, Monty, Arnie and Brooks. Plus - of course - TC's extensive list of other possible infractions we'll save for another day. Timestamps 0:00 - Intro 5:10 - Tiger's drop at the 2013 Masters 34:15 - 1987 Craig Stadler TowelGate 1:01:30 - Monty's Jakarta incident 1:13:05 - Arnie at the 1958 Masters 1:34:45 - Brooks at the 2023 Masters Show Notes: Golf Digest Video on the 2013 Tiger Drop Join us in our support of the Evans Scholars Foundation: ⁠⁠⁠⁠https://nolayingup.com/esf⁠ Support our Sponsors: Titleist Rhoback Lagoon If you enjoyed this episode, consider joining⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ The Nest⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠: No Laying Up's community of avid golfers. Nest members help us maintain our light commercial interruptions (3 minutes of ads per 90 minutes of content) and receive access to exclusive content, discounts in the pro shop, and an annual member gift. It's a $90 annual membership, and you can sign up or learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠nolayingup.com/join⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Subscribe to the No Laying Up Newsletter here: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://newsletter.nolayingup.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Subscribe to the No Laying Up Podcast channel here: https://www.youtube.com/@NoLayingUpPodcast Learn more about your ad choices. Visit megaphone.fm/adchoices

Roland Cox is the founder and creator of the Daddy Builders Network. Daddy Builders Network is designed to give Daddies hope, encouragement, information, strategies, and ideas to equip them to become and remain active in the lives of their children.   Roland is married to Michelle, and they've been married 13 years (been together for 20 years). And together they have two children, Makayla (14) and Monty (11). And they've raised Destiny, Roland's 22 year-old daughter, for the past 11 years.   To contact Roland Cox, visit his website at http://www.DaddyBuildersNetwork.org or email him at info@daddybuildersnetwork.org    ----------------------     Talk with Dr. Joe 1-on-1: Are you tired and stuck? Want to go to get your faith, marriage, family, career and finances back on track?  Then maybe it's time you got a coach. Every CHAMPION has one. Schedule an appointment to chat with Dr. Joe. He takes on only a few Breakthrough Calls each week.  The call is FREE, but slots are limited to ONE call only.  NO RESCHEDULES.  Just click on the link below and select the BREAKTHROUGH CALL option to set up an appointment: http://TalkwithDrJoe.com  If no slots are available, please check back in a week.   Also join us on: Online Podcast Community (on Station):  https://station.page/realmen Facebook: @realdrjoemartin YouTube: http://www.RealMenTraining.com Instagram: @realdrjoemartin Twitter: @professormartin Website: https://RealMenConnect.com